MedTrace Logo

Secretin Infusion for Pain Due to Chronic Pancreatitis

NCT01265875 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-03-09

Study results available
· View outcomes & findings →

Summary

* To determine if intravenous secretin administration in escalating doses three times daily for three days will improve the pain from CP at the time of infusion, after each infusion (1 to 3 hours), at Day 7 after infusion, and at Day 30 after infusion.
* To validate the safety of intravenous secretin administration at the dosage indicated in this study.

Conditions

  • Chronic Pancreatitis

Interventions

DRUG

Human Secretin

Dose Escalation

Sponsors & Collaborators

  • Dartmouth-Hitchcock Medical Center

    collaborator OTHER

  • ChiRhoClin, Inc.

    lead INDUSTRY

Principal Investigators

  • Timothy B Gardner, M.D. · Dartmouth-Hitchcock Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-12-31
Completion
2012-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01265875 on ClinicalTrials.gov